At the World Glaucoma Congress (WGC) in Rome, Italy this summer, Ciliatech presented preliminary results of the second 2-year postoperative clinical trial (SAFARI Ⅱ) on its Cilioscleral Interposition Device (CID). The device, a 26% hydrophilic acrylic implant, is designed to lower intraocular pressure without entering the anterior chamber and without bleb…
Study will evaluate INTERCIL in patients with primary open-angle glaucoma as Ciliatech advances US clinical development program Epagny Metz-Tessy, France, September 8, 2026 – Ciliatech, ....
Ciliatech is pleased to announce the publication of 24-month clinical data for INTERCIL® in Ophthalmology and Therapy. The publication, titled “A Prospective Evaluation of the ....
Ciliatech are delighted to announce the appointment of Saima Khokhar as International Scientific & Medical Affairs Manager, joining the company on a full-time basis to ....
This site is only for the use of professionals associated with the field of Ophthalmology and is not intended for patients.